Literature DB >> 27693493

miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin.

Dibash K Das1, Michelle Naidoo2, Adeodat Ilboudo2, Jong Y Park3, Thahmina Ali2, Konstantinos Krampis4, Brian D Robinson5, Joseph R Osborne6, Olorunseun O Ogunwobi7.   

Abstract

Prostate cancer (PCa) is frequently diagnosed in men, and dysregulation of microRNAs is characteristic of many cancers. MicroRNA-1207-3p is encoded at the non-protein coding gene locus PVT1 on the 8q24 human chromosomal region, an established PCa susceptibility locus. However, the role of microRNA-1207-3p in PCa is unclear. We discovered that microRNA-1207-3p is significantly underexpressed in PCa cell lines in comparison to normal prostate epithelial cells. Increased expression of microRNA-1207-3p in PCa cells significantly inhibits proliferation, migration, and induces apoptosis via direct molecular targeting of FNDC1, a protein which contains a conserved protein domain of fibronectin (FN1). FNDC1, FN1, and the androgen receptor (AR) are significantly overexpressed in PCa cell lines and human PCa, and positively correlate with aggressive PCa. Prostate tumor FN1 expression in patients that experienced PCa-specific death is significantly higher than in patients that remained alive. Furthermore, FNDC1, FN1 and AR are concomitantly overexpressed in metastatic PCa. Consequently, these studies have revealed a novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in PCa.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgen receptor; Fibronectin; Fibronectin type III domain containing 1; MiR-1207-3p; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27693493      PMCID: PMC5077722          DOI: 10.1016/j.yexcr.2016.09.021

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  53 in total

Review 1.  Fibronectin at a glance.

Authors:  Roumen Pankov; Kenneth M Yamada
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

2.  Structural design and molecular evolution of a cytokine receptor superfamily.

Authors:  J F Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.

Authors:  Junjie Yu; Youyi Lu; Di Cui; Enhui Li; Yipin Zhu; Yuyang Zhao; Fujun Zhao; Shujie Xia
Journal:  Oncol Rep       Date:  2013-12-05       Impact factor: 3.906

Review 5.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

Review 6.  Role of epithelial mesenchymal transition in prostate tumorigenesis.

Authors:  Mohammad Imran Khan; Abid Hamid; Vaqar Mustafa Adhami; Rahul K Lall; Hasan Mukhtar
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  Risk stratification of prostate cancer patients based on EPS-urine zinc content.

Authors:  Zdravka Medarova; Subrata K Ghosh; Mark Vangel; Richard Drake; Anna Moore
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

8.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Authors:  Jacques Lapointe; Chunde Li; John P Higgins; Matt van de Rijn; Eric Bair; Kelli Montgomery; Michelle Ferrari; Lars Egevad; Walter Rayford; Ulf Bergerheim; Peter Ekman; Angelo M DeMarzo; Robert Tibshirani; David Botstein; Patrick O Brown; James D Brooks; Jonathan R Pollack
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-07       Impact factor: 11.205

9.  The identification of microRNAs in a genomically unstable region of human chromosome 8q24.

Authors:  Konrad Huppi; Natalia Volfovsky; Timothy Runfola; Tamara L Jones; Mark Mackiewicz; Scott E Martin; J Frederic Mushinski; Robert Stephens; Natasha J Caplen
Journal:  Mol Cancer Res       Date:  2008-02       Impact factor: 5.852

10.  Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis.

Authors:  Emily A Matuszak; Natasha Kyprianou
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05
View more
  24 in total

1.  High FNDC1 expression correlates with poor prognosis in gastric cancer.

Authors:  Muxiao Zhong; Yijie Zhang; Fangfang Yuan; Yao Peng; Jingjing Wu; Jiawei Yuan; Wei Zhu; Yali Zhang
Journal:  Exp Ther Med       Date:  2018-09-12       Impact factor: 2.447

2.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

Review 3.  Androgen receptor and miR-206 regulation in prostate cancer.

Authors:  Fu Y Chua; Brian D Adams
Journal:  Transcription       Date:  2017-06-09

4.  Rutin suppresses FNDC1 expression in bone marrow mesenchymal stem cells to inhibit postmenopausal osteoporosis.

Authors:  Yuhong Xiao; Ran Wei; Zhen Yuan; Xiaoyong Lan; Jin Kuang; Dongxia Hu; Yi Song; Jun Luo
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

5.  Expression profiling of microRNAs in human bone tissue from postmenopausal women.

Authors:  Laura De-Ugarte; Jenny Serra-Vinardell; Lara Nonell; Susana Balcells; Magdalena Arnal; Xavier Nogues; Leonardo Mellibovsky; Daniel Grinberg; Adolfo Diez-Perez; Natalia Garcia-Giralt
Journal:  Hum Cell       Date:  2017-09-20       Impact factor: 4.174

6.  A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer.

Authors:  Dibash K Das; Olorunseun O Ogunwobi
Journal:  RNA Dis       Date:  2017-02-06

7.  [FNDC1 is highly expressed in lung adenocarcinoma and closely related with poor prognosis].

Authors:  H Hong; H Zhu; C Li; C Zang; H Sang; L Chen; A Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

8.  Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Authors:  Robert J Rounbehler; Anders E Berglund; Travis Gerke; Mandeep M Takhar; Shivanshu Awasthi; Weimin Li; Elai Davicioni; Nicholas G Erho; Ashley E Ross; Edward M Schaeffer; Eric A Klein; R Jeffrey Karnes; Robert B Jenkins; John L Cleveland; Jong Y Park; Kosj Yamoah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-14       Impact factor: 4.254

9.  Fibronectin and androgen receptor expression data in prostate cancer obtained from a RNA-sequencing bioinformatics analysis.

Authors:  Dibash K Das; Thahmina Ali; Konstantinos Krampis; Olorunseun O Ogunwobi
Journal:  Data Brief       Date:  2017-02-03

10.  Sea turtle fibropapilloma tumors share genomic drivers and therapeutic vulnerabilities with human cancers.

Authors:  David J Duffy; Christine Schnitzler; Lorraine Karpinski; Rachel Thomas; Jenny Whilde; Catherine Eastman; Calvin Yang; Aleksandar Krstic; Devon Rollinson; Bette Zirkelbach; Kelsey Yetsko; Brooke Burkhalter; Mark Q Martindale
Journal:  Commun Biol       Date:  2018-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.